Net Income

Jiuzi Holdings announced a $4M offering, tanking its stock. Then, news of a $1B crypto funding plan sent it soaring. A deep dive into a high-stakes pivot.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?

Boston's Weiss Asset Management reveals a strategic 4.17% derivative stake in International Personal Finance as a takeover deadline looms.

A deep dive into Perma-Pipe's record-breaking quarter, revealing a strategy of regional dominance and savvy diversification into high-growth tech sectors.

Nordic American Tankers is riding a wave of record profits, but the industry's future hinges on volatile markets and the shadow of Venezuelan oil.

Amid a major corporate overhaul, Emergent BioSolutions secures a key FDA approval, signaling a new era for the firm and for U.S. biodefense strategy.

A sustainable energy firm eyes $75M in fees from a $300M Ripple Labs share deal in South Korea. Is this a genius, capital-light move into crypto?

A top proxy advisory firm urges shareholders to reject Alcon's bid for STAAR Surgical, empowering an activist investor's high-stakes governance fight.

Fresh off its IPO, iOThree is pushing AI and certified digital tools. Can its innovation engine and Asian expansion overcome market headwinds?

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

Acadia's new powder form of the only Rett syndrome drug offers families vital choice, easing daily care and showing the power of patient-led innovation.

A Maryland community bank is voluntarily leaving Nasdaq. We analyze why shedding public market burdens is an increasingly popular survival strategy.

Beyond the dividend payout, Cherry Hill Mortgage's strategy reveals a deeper pivot towards digital innovation, balancing high yields with new frontiers of risk.

As logistics giant Ryder plans a seamless CEO shift from Sanchez to insider John Diez, we analyze the strategy of continuity in a volatile market.

With over 123 million displaced, refugee camps are now de facto cities. Temporary water solutions are fueling disease, making the case for permanent fixes.

Malaysia's Treasure Global secures fresh capital, but a brutal market reaction and high cash burn raise questions about its super app's future.

A $277M secondary offering sees MIAX shareholders cash in, but the company itself isn't taking any money. Here’s what that says about its financial power.

An independent study shows Mesoblast’s cell therapy has superior remission rates over a market leader, hinting at a new standard of care and a big win for investors.

Lument Finance Trust's latest dividend boasts an attractive yield, but recent adjustments raise questions about the health of commercial real estate.